

Fig. S1. The percentage of patients reporting improvement in individual ADCT (Atopic Dermatitis Control Tool) categories following treatment with either cyclosporine or dupilumab. Each panel represents a different ADCT category, with the proportion of patients experiencing improvement denoted in dark green (Yes) and those without improvement in light green (No). The results are based solely on the initial assessment of discomfort within these categories. ADCT-1: overall severity of symptoms, ADCT-2: frequency of severe itching episodes, ADCT-3: level of discomfort, ADCT-4: sleep disturbances, ADCT-5: disruption to daily activities, ADCT-6: emotional or mood impacts

